Reaction
Metastatic Renal Cell Carcinoma reporting signals
As of the last recalculation, Metastatic Renal Cell Carcinoma appears in 1,831 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is SUNITINIB MALATE (PRR 378.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sunitinib Malate | 764 | 378.3 | 385.8 |
| Axitinib | 209 | 137.6 | 139.0 |
| Pazopanib Hydrochloride | 175 | 81.2 | 81.7 |
| Sorafenib | 104 | 60.3 | 60.6 |
| Everolimus | 143 | 34.6 | 34.7 |
| Everolimus Tablets | 46 | 32.0 | 32.0 |
| Cabozantinib | 96 | 23.9 | 24.0 |
| Dronabinol | 8 | 11.4 | 11.4 |
| Nivolumab | 74 | 9.0 | 9.0 |
| Prochlorperazine Maleate | 7 | 8.7 | 8.7 |
| Loperamide Hydrochloride And Dimethicone | 24 | 8.6 | 8.6 |
| Terazosin Hydrochloride | 6 | 7.7 | 7.7 |
| Thalidomide | 20 | 6.2 | 6.3 |
| Lenvatinib | 15 | 5.2 | 5.2 |
| Ipilimumab | 15 | 4.0 | 4.0 |